Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Retained Earnings: 2020-2025

Historic Retained Earnings for Relay Therapeutics (RLAY) over the last 6 years, with Sep 2025 value amounting to -$2.0 billion.

  • Relay Therapeutics' Retained Earnings fell 17.65% to -$2.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.0 billion, marking a year-over-year decrease of 17.65%. This contributed to the annual value of -$1.7 billion for FY2024, which is 24.11% down from last year.
  • According to the latest figures from Q3 2025, Relay Therapeutics' Retained Earnings is -$2.0 billion, which was down 5.26% from -$1.9 billion recorded in Q2 2025.
  • Relay Therapeutics' 5-year Retained Earnings high stood at -$446.4 million for Q1 2021, and its period low was -$2.0 billion during Q3 2025.
  • For the 3-year period, Relay Therapeutics' Retained Earnings averaged around -$1.6 billion, with its median value being -$1.6 billion (2024).
  • Data for Relay Therapeutics' Retained Earnings shows a maximum YoY crashed of 165.38% (in 2021) over the last 5 years.
  • Relay Therapeutics' Retained Earnings (Quarterly) stood at -$768.1 million in 2021, then plummeted by 37.82% to -$1.1 billion in 2022, then slumped by 32.30% to -$1.4 billion in 2023, then dropped by 24.11% to -$1.7 billion in 2024, then decreased by 17.65% to -$2.0 billion in 2025.
  • Its Retained Earnings was -$2.0 billion in Q3 2025, compared to -$1.9 billion in Q2 2025 and -$1.8 billion in Q1 2025.